AU2016214059B2 - Anti-salmonella antibodies and uses thereof - Google Patents

Anti-salmonella antibodies and uses thereof Download PDF

Info

Publication number
AU2016214059B2
AU2016214059B2 AU2016214059A AU2016214059A AU2016214059B2 AU 2016214059 B2 AU2016214059 B2 AU 2016214059B2 AU 2016214059 A AU2016214059 A AU 2016214059A AU 2016214059 A AU2016214059 A AU 2016214059A AU 2016214059 B2 AU2016214059 B2 AU 2016214059B2
Authority
AU
Australia
Prior art keywords
antibody
gly
ser
salmonella
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016214059A
Other languages
English (en)
Other versions
AU2016214059A1 (en
Inventor
Saeid Babaei
Ali RIAZI
Dea SHAHINAS
Rashida WILLIAMS
Zhun YAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abcelex Technologies Inc
Original Assignee
Abcelex Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcelex Tech Inc filed Critical Abcelex Tech Inc
Publication of AU2016214059A1 publication Critical patent/AU2016214059A1/en
Application granted granted Critical
Publication of AU2016214059B2 publication Critical patent/AU2016214059B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
AU2016214059A 2015-02-04 2016-02-03 Anti-salmonella antibodies and uses thereof Ceased AU2016214059B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112035P 2015-02-04 2015-02-04
US62/112,035 2015-02-04
PCT/IB2016/050546 WO2016125089A1 (en) 2015-02-04 2016-02-03 Anti-salmonella antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2016214059A1 AU2016214059A1 (en) 2017-07-20
AU2016214059B2 true AU2016214059B2 (en) 2021-08-05

Family

ID=56563529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016214059A Ceased AU2016214059B2 (en) 2015-02-04 2016-02-03 Anti-salmonella antibodies and uses thereof

Country Status (6)

Country Link
US (2) US10421806B2 (enExample)
EP (1) EP3253789A4 (enExample)
JP (2) JP2018511303A (enExample)
AU (1) AU2016214059B2 (enExample)
CA (1) CA2972568A1 (enExample)
WO (1) WO2016125089A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102165777B1 (ko) * 2016-04-06 2020-10-14 주무토르 바이오로직스 인코포레이티드 단백질의 클로닝 및 발현을 위한 벡터, 그 방법 및 적용
MX2020008208A (es) * 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
WO2021197358A1 (zh) * 2020-03-31 2021-10-07 普米斯生物技术(珠海)有限公司 一种抗pd-l1和pd-l2抗体及其衍生物和用途
CN112707963A (zh) * 2021-01-26 2021-04-27 西北农林科技大学 广谱识别沙门氏菌的纳米抗体、重组载体、宿主细胞及其应用
WO2025111553A2 (en) * 2023-11-22 2025-05-30 The General Hospital Corporation Antibody-based human lamp-1 composition and its uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0915158A3 (en) * 1997-11-04 1999-10-20 Unilever N.V. Improvements in or relating to detection of salmonella
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
MX2013008736A (es) * 2011-01-28 2013-11-22 Ca Nat Research Council Diseño de dominios de inmunoglobulina.
AU2015237933B2 (en) * 2014-03-27 2020-09-17 Sambuddha GHOSH Expression of a single chain antibody against Salmonella in Lactobacillus

Also Published As

Publication number Publication date
US20200040067A1 (en) 2020-02-06
US10421806B2 (en) 2019-09-24
EP3253789A1 (en) 2017-12-13
EP3253789A4 (en) 2018-11-14
WO2016125089A1 (en) 2016-08-11
AU2016214059A1 (en) 2017-07-20
JP2020120667A (ja) 2020-08-13
US20180030120A1 (en) 2018-02-01
CA2972568A1 (en) 2016-08-11
JP2018511303A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
US20200040067A1 (en) Anti-salmonella antibodies and uses thereof
Riazi et al. Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens
US10259864B2 (en) Anti-campylobacter jejuni antibodies and uses therefor
McNeilly et al. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157: H7 following oral challenge
US20210269512A1 (en) Antibodies against disease causing agents of poultry and uses thereof
US11939371B2 (en) Antibodies against microorganisms and uses thereof
JP2018511303A5 (enExample)
AU2020202611A1 (en) Binding moieties for biofilm remediation
RU2766354C2 (ru) Вакцинные конструкты и их применения против инфекций стафилококка
Punyokun et al. The production of anti-Vibrio harveyi egg yolk immunoglobulin and evaluation of its stability and neutralisation efficacy
Hunault Identification and evaluation of monoclonal antibodies against Surface-Layer Proteins of Clostridioides difficile
Meinen-Jochum Usage of segmented filamentous bacteria as a prophylactic to improve gut immune maturation in chickens
Riazi et al. Pentavalent Single Domain Antibodies Reduce Campylobacter jejuni Motility and
CN118510541A (zh) 多价抗弯曲杆菌抗体和疫苗
Ruland Exposure of Atlantic salmon (Salmo salar L.) to non-virulent strains of Y. ruckeri to protect against subsequent infection with virulent Y. ruckeri
Almario Prevalence of Salmonella on laying hen farms and control of colonization in poultry through egg yolk antibodies
CN101861329A (zh) 作为抗弯曲菌的抗微生物剂的肽
Ghunaim Campylobacter jejuni colonization of broiler chickens
Mohawk Impact of Anti-Shiga Toxin Type 2 (Stx2) Neutralizing Antibody on Colonization and Pathogenesis of Escherichia Coli O157: H7 in Mice

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired